Central Vermont Medical Center/National Life Cancer Treatment

Summary

Central Vermont Medical Center/National Life Cancer Treatment is a medical facility located in Montpelier, Vermont. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Central Vermont Medical Center/National Life Cancer Treatment is involved with conducting 124 clinical trials across 300 conditions. There are 16 research doctors associated with this hospital, such as Alissa Thomas, Steven Ades, M.D., Marie Wood, and Nataniel H. Lester-Coll.

Top PIs

Clinical Trials running at Central Vermont Medical Center/National Life Cancer Treatment

Prostate Cancer

Esophageal cancer

Testicular cancer

Bladder Cancer

Cutaneous Melanoma

Lung Cancer

Esophageal Adenocarcinoma

Gastric cancer

Gastroesophageal Junction Adenocarcinoma

Esophageal Cancer

Shorter vs Usual Radiation Therapy

for Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.

Recruiting

2 awards

Phase 3

10 criteria

Standard Therapy + Surgery/Radiation

for Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.

Recruiting

2 awards

Phase 3

30 criteria

Relugolix + Radiation

for Advanced-Stage Prostate Cancer

This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited other parts of the body (oligometastatic). Relugolix is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone (a male hormone) produced by the body. It may stop the growth of cancer cells that need testosterone to grow. Radiation therapy uses high-energy x rays or protons to kill tumor cells. The addition of relugolix to the radiation may reduce the chance of oligometastatic prostate cancer spreading further.

Recruiting

0 awards

Phase 2